Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Phathom Pharmaceuticals, Inc. (PHAT)

Phathom says FDA opened public docket on VOQUEZNA exclusivity; comments due Nov. 23, 2026

Negative Impact 3 of 5 legal/regulatory Written later

Phathom Pharmaceuticals said the FDA has opened a public docket to seek comment on legal and regulatory questions tied to a challenge by generic filer BDR Pharmaceuticals over VOQUEZNA's exclusivity. The challenge follows FDA's June 6, 2025 decision that VOQUEZNA has 10 years of NCE exclusivity through May 3, 2032. If the challenge succeeds, exclusivity could be shortened and competing generic applications could be approved earlier than expected.

Key points

  • FDA docket No. FDA-2026-N-13038; comments due November 23, 2026
  • FDA's June 6, 2025 decision granted Phathom's Citizen Petition, recognizing NCE exclusivity through May 3, 2032
  • A second purported ANDA filer, Saba Ilac Sanayii Ve Ticaret AS, says it has a related case and plans to seek consolidation with BDR's case
  • Phathom believes the exclusivity remains in effect and will say so in its FDA comments and in court

The filing

CompanyPhathom Pharmaceuticals, Inc. (PHAT)
Form8-K, current report
Filed with the SECOct 26, 2026, 6:02 AM ET
Accession number0001193125-26-430977

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.